Sponsor Pipeline

Aptabio Therapeutics, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
3
Recruiting
1
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-07 NCT05758896
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI		 Trial completed
2026-08-07 NCT05758896
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI		 date change Completion moved earlier: 2026-12-31 -> 2026-07-22
Active Trials by Phase
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06962098 Efficacy and Safety Study of Isuzinaxib in Subjects With DKD Diabetic Kidney Disease (DKD) Recruiting
Phase 1
NCT07123415 A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in… Advanced Solid Cancer Recruiting
NCT07330674 A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses Age Related Macular Degeneration (ARMD) Recruiting
Disease Areas
Chronic Kidney Disease (1)
Get alerts when Aptabio Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free